In recent years and across multiple lines of therapy, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with hormonal therapy has become a standard of care for patients with advanced, hormone-receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer. As previously reported, in the PALOMA-3 trial (N = 521) the combination of the CDK4/6 […]
